Medicine and Dentistry
Gastrectomy
100%
Stomach Cancer
61%
Abdominal Cancer
58%
Retrospective Study
39%
Retrospective Cohort Study
24%
Nivolumab
23%
Surgeon
21%
Neoplasm
18%
Total Stomach Resection
13%
Disease
13%
Esophagectomy
13%
Monotherapy
13%
Da Vinci Surgical System
13%
Deep Vein Thrombosis
11%
Venous Thromboembolism
11%
Reflux Esophagitis
11%
Second-Line Chemotherapy
11%
Esophageal Cancer
11%
Gastrointestinal Stromal Tumor
11%
Early Intervention
11%
Conversion Therapy
11%
Minimally Invasive Surgery
11%
Esophagogastrostomy
11%
Imatinib
11%
Esophagoscopy
11%
Kocher Manoeuvre
11%
Neoadjuvant Chemotherapy
11%
Pylorus Stenosis
11%
Stomach Partitioning
11%
Gastrojejunostomy
11%
Minimally Invasive Procedure
11%
Pancreas Fistula
11%
Lymphocyte
11%
Postoperative Complication
10%
Retroperitoneal Lymph Node Dissection
10%
Bleeding
9%
Clinical Stage
7%
Overall Survival
7%
Adverse Event
7%
Diseases
6%
Body Mass Index
6%
Platelet
5%
Neutrophil
5%
Progressive Disease
5%
Multivariate Analysis
5%
Operation Duration
5%
Recurrent Disease
5%
Recurrence Free Survival
5%
Odds Ratio
5%
Surgery
5%
Keyphrases
Gastric Cancer
61%
Clinical Experience
23%
Robotic Gastrectomy
18%
Oncological Safety
14%
Single Institution
13%
Surgical Robot
13%
Laparoscopic Gastrectomy
13%
Layer-oriented
11%
Chemotherapy
11%
Technical Aspects
11%
Second-line Chemotherapy
11%
Nivolumab
11%
Tolerability
11%
Hinotori
11%
Esophageal Cancer
11%
Retrospective Review
11%
Disease Control
11%
Conversion Therapy
11%
Standardized Procedure
11%
Killian-Jamieson Diverticulum
11%
Kocher Maneuver
11%
Robot-assisted Minimally Invasive Esophagectomy (RAMIE)
11%
Local Gastrectomy
11%
Predictive Models
11%
Postoperative Pancreatic Fistula
11%
Pancreatic Fistula
11%
Minimally Invasive Surgery
11%
Endoscopic Surgical Skill Qualification System
11%
Single Center
11%
Retrospective Cohort Study
11%
Robotic Distal Gastrectomy
11%
Single-center Retrospective Study
11%
Da Vinci Xi System
11%
CRP to Albumin Ratio
10%
Blood Loss
10%
Operative Time
10%
Clinical Stage I
8%
Transnational
7%
Intraoperative Adverse Events
7%
R0 Resection
6%
Postoperative Complications
6%
Standard Lymphadenectomy
5%
Tumor
5%
Qualified Surgeon
5%
Over 65
5%
Third-line Chemotherapy
5%
Progressive Disease
5%
Disease Groups
5%
Odds Ratio
5%